Oncolytic Viral Therapy Market to Grow via Immunotherapy Advances by 2025-2033 | Amgen, Inc., Daiichi Sankyo Co., Ltd., Lokon Pharma AB

Oncolytic Viral Therapy Market Size reached US$ 24.48 Million in 2024 and is expected to reach US$ 164.51 Million by 2033, growing at a CAGR of 23.8% during the forecast period 2025-2033.

The latest Oncolytic Viral Therapy Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/oncolytic-viral-therapy-market?ophp

Oncolytic viral therapy uses genetically modified viruses to selectively infect and destroy cancer cells while stimulating an immune response. This novel therapeutic class is gaining attention as clinical trials show promise in treating solid tumors, supported by immunotherapy advancements and personalized oncology approaches.

Oncolytic Viral Therapy Market Competitors Overview:

Amgen, Inc., Daiichi Sankyo Co., Ltd., Lokon Pharma AB, Virogin Biotech Canada Ltd, KaliVir Immunotherapeutics, Inc., Transgene SA, Vyriad, Inc., Coastar Theapeutics Inc., IconOVir Bio, Inc., and Calidi Biotherapeutics, Inc., among others.

Important Industry Updates of 2024 and 2025:

✅ In June 2025 BioNTech Acquires CureVac In a major move to expand its oncology pipeline, BioNTech completed a $1.25 billion all-stock acquisition of CureVac. This deal enhances BioNTech's capabilities in RNA-based immunotherapies, particularly in cancer, and reflects its strategic shift beyond COVID-19 vaccines into next-gen oncolytic viral platforms.

✅ In March 2025 AstraZeneca announced its acquisition of EsoBiotec, a pioneer in in vivo CAR-T and oncolytic virus-based immunotherapy, for up to $1 billion. The deal includes a $425 million upfront payment and milestone-based additions. This strategic acquisition positions AstraZeneca to lead in scalable cancer immunotherapies delivered via injection.

In 2025, Synthetic Biologics took a significant step in solid tumor therapies by acquiring VCN Biosciences, known for its oncolytic adenovirus platform targeting pancreatic and other hard-to-treat cancers. This acquisition supports Synthetic's long-term goal of building a robust immuno-oncology portfolio addressing high unmet clinical needs.

Oncolytic Viral Therapy Market Segments Overview:

∎By Virus Type (Adenoviruses, Herpes Simplex Virus, Maraba Virus, Measles, Newcastle Disease Virus, Picornavirus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus, and Others)
∎By Application (Melanoma, Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Cancer, and Others)
∎By Mode of Administration (Intratumoral Injection, Intravenous Infusion, Intracavitary Injection, and Others)
∎By End-User (Hospitals, Oncology Centers, Ambulatory Surgical Centers, Cancer Research Institutes, and Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oncolytic-viral-therapy-market?ophp

Methodology and Scope:

This Oncolytic Viral Therapy Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.

Regional Overview for Oncolytic Viral Therapy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=oncolytic-viral-therapy-market?ophp

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➤ What are the global sales, production, import, and export trends in the Oncolytic Viral Therapy market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the Oncolytic Viral Therapy market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.